|
Wednesday, November 16, 2016
Print Current Session:
 |
|
|
Wednesday
SESSION 37:
NEW DEVELOPMENTS IN VASCULAR CARE, DRGs, TELEMEDICINE, REIMBURSEMENTS, REPORTING BAD PRACTICE AND THE FDA
Moderators:Bruce A. Perler, MD, MBA / Ronald M. Fairman, MD
|
|
| SESSION 37 SCHEDULE | |
| 3:40 PM - 3:45 PM | How Does A Real-Time Dashboard Database Improve The Quality And Decrease The Cost Of Vascular Care |
| Presenter(s):Timothy M. Sullivan, MD | |
| View Slides in PDF | |
| 3:46 PM - 3:51 PM | How Can Hospitalists Improve A Vascular Service By Decreasing Mortality, Length Of Stay And Readmissions |
| Presenter(s):Peter L. Faries, MD, FACS | |
| View Slides in PDF | |
| 3:52 PM - 3:57 PM | Volume/Outcome Relationship With CEA And CAS: German Registry Data From 175,000 Patients |
| Presenter(s):Hans-Henning Eckstein, MD, PhD | |
| View Slides in PDF | |
| 3:58 PM - 4:03 PM | Hospital Volume Matters Most In Improving Outcome Of EVAR: Both Surgeon And Hospital Volume Matter For Open AAA Repair |
| Presenter(s):Marc L. Schermerhorn, MD | |
| View Slides in PDF | |
| 4:04 PM - 4:09 PM | How To Incorporate Virtual Visits Into A Vascular Practice: The Technology Is Here: What Is The Technology And How To Use It |
| Presenter(s):John (Jeb) W. Hallett, MD | |
| View Slides in PDF | |
| 4:10 PM - 4:15 PM | Role Of Telemedicine In A Vascular Practice: How To Be Reimbursed For It |
| Presenter(s):Clifford M. Sales, MD, MBA, FACS | |
| View Slides in PDF | |
| 4:16 PM - 4:21 PM | Benefit Of New AAA/EVAR DRGs On Hospital Economics: They Are A Game Changer And How They Can Benefit Vascular Surgeons |
| Presenter(s):W. Charles Sternbergh III, MD | |
| View Slides in PDF | |
| 4:22 PM - 4:27 PM | We Have A Duty To Report Unethical Procedures Or Malpractice To Hospital Administrators, State Misconduct Boards And Patients Seeking A Second Opinion: Why It Does Not Happen And What To Do If Such Reporting Does No Good Because Of Administrator Inaction |
| Presenter(s):O. William Brown, MD, JD | |
| View Slides in PDF | |
| 4:28 PM - 4:33 PM | Ezetimbe (Zetia) Lowers LDL-C And Decreases Cardiovascular Death, MI And Stroke Over Statins Alone: When Should It Be Given And Why Didn’t The FDA Approve It |
| Presenter(s):Russell H. Samson, MD, RVT, FACS | |
| View Slides in PDF | |
| 4:34 PM - 4:39 PM | Why Does The FDA Approve Lower Extremity Devices With Only 6-12 Months Follow-Up: Shouldn’t Longer Durability Be Required |
| Presenter(s):Dorothy B. Abel, BSBME | |
| View Slides in PDF | |
| 4:40 PM - 4:46 PM | Panel Discussion |
| END OF SESSION 37 | |
| previous | next |